SAFYHR AWARD 2027

SANOFI AWARD

FOR YOUNG HEMATOLOGIST RESEARCHER

The Belgian Hematology Society (BHS), with the support of an unrestricted grant from Sanofi, has the pleasure to announce the “SAFYHR Award”.

Young oncologists in training a reinvied to submit their project and apply for The Sanofi Award For Young Hematologist Researcher.

Terms and condition to apply are available on the BHS website. The deadline of submission is **Monday, 04 January 2027 (midnight CET).**

The “SAFYHR award” jury will select only one (1) innovating project which will be awarded with 15.000 euro. The award ceremony will take place during the **42nd BHS General Annual Meeting, March 12-13, 2027.**

We are looking forward to receiving outstanding projects that can change the natural history of hematological diseases.

Sincerely,
Ann De Becker, President of the BHS

SCAN ME TO APPLY

Award Criteria

Who can apply? →

Young hematologists or and pediatric hematooncologists in training who are MDs and are within 10 years after MD graduation

- Young researchers (PhD student) with a hematologist as their promoter or co-promoter

Which projects are eligible? →

The topic of research is related to translational research within the field of hematology

Application requirements? →

Description of the research project including costs and time frame (max. 2 pages)

- Letter of support by a promotor from the department where the research will be performed (max. 1 page)

- Motivational letter (max. 1 page)

- List of publications (if applicable)

- CV

Application forms are available on the BHS website https://www.bhs.be/en/projects-and-grants/bhsawards/safyrh-award and **must be submitted by January 4th 2027.**
Only submission through the online form is possible.
Submissions sent by e-mail will not be considered.

BHS
Belgian Hematology Society

Contact BHS Secretariat
Rue de la loi / Wetstraat 42,
1040 Brussels, Belgium
bhs@seauton-international.com
www.bhs.be

sanofi

Sanofi Belgium, MAT-BE-2501234
The SAFYHR award has been made possible with an unrestricted grant from Sanofi.